PT-141 (Bremelanotide) acts on central receptors without directly affecting blood vessels or hormones. It enhances psycho-emotional and physical sexual arousal in both men and women. It is particularly effective for sexual disorders caused by stress or fatigue.
Raw MaterialUSA
Country of OriginUAE
Purity99%
Raw MaterialUSA
Purity99%
Country of OriginUAE
Indications
Female hypoactive sexual desire
Erectile dysfunction without organic pathology
Post-stress sexual disorders
Support for chronic fatigue.
Contraindications
Decompensated arterial hypertension
Pregnancy
Hypersensitivity to melanocortins
Psychiatric disorders in an acute phase.
PT-141 delivers a highly concentrated form of the neuropeptide for rapid activation of central arousal pathways. Its fast bioavailability enables immediate engagement of melanocortin circuits responsible for libido, heightened sen...
PT-141 delivers a highly concentrated form of the neuropeptide for rapid activation of central arousal pathways. Its fast bioavailability enables immediate engagement of melanocortin circuits responsible for libido, heightened sensitivity, and vascular reaction.
Unlike peripheral vasodilators such as Sildenafil, which primarily enhance blood flow, PT-141 directly stimulates MC3R/MC4R receptors in the hypothalamus - regions governing sexual interest, motivation, and cognitive-emotional response to stimuli. As a result, the effect is more comprehensive, integrating vascular, neurochemical, and motivational components of sexual function.
The peptide further boosts neuro-sensory responsiveness, reduces stress-induced inhibitory signaling, and supports emotional-motivational pathways. The ampoule format is especially valuable at the beginning of a protocol when a pronounced early response is desired.
PT-141 is suitable for patients who need a fast, noticeable effect - in cases of chronic stress, decreased interest, hormonal transitions, or emotional factors impacting sexual desire. It is used in sexual-health programs, neurochemical regulation strategies, and recovery schemes targeting reduced motivational and arousal response.